- Oxygen Biotherapeutics (OXBT +20%) pops after the USPTO issued the drug developer a patent earlier today for its treatment for pruritus - a sensation patients instinctually try to relieve by rubbing or scratching.
- The company says it's currently evaluating commercialization strategies, which potentially includes out-licensing for conditions such as allergic contact dermatitis, psoriasis and acne.
Oxygen Biotherapeutics jumps on issuance of patent for its treatment of pruritus
From other sites
at CNBC.com (Jun 25, 2014)
at CNBC.com (Mar 31, 2014)
at CNBC.com (Mar 17, 2014)
at CNBC.com (Mar 4, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs